Spain's Reig Jofre to produce Janssen's COVID-19 vaccine candidate

15 December 2020
coronavirus_credit_deposit_photos-_largre

Spanish pharma company Reig Jofre’s (BME: RJF) share price rocketed 32% to 4.99 euros this morning, after it revealed that it has reached an agreement with Johnson & Johnson (NYSE: JNJ) subsidiary Janssen to execute the technology transfer to manufacture its investigational COVID-19 vaccine candidate, Ad26.COV2-S.

Reig Jofre’s long standing, widely recognized experience in the manufacturing of sterile injectable products, together with the availability of a state-of-the-art new Plant in Barcelona scheduled to come on-stream in the first quarter of 2021, create a unique opportunity to contribute to the need for a fast and secure deployment of the COVID-19 vaccine candidate.

Investment in Barcelona plant

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology